



Recruitment of the First Participant in a Human Study for evaluating screening technique for retinal ophthalmic conditions

June 2, 2024

BioLight [TASE: BOLT] is pleased to announce that on May 30, 2024, the first participant was recruited in a clinical feasibility study in humans for evaluating innovative technique with potential to diagnose various retinal ophthalmic conditions by analyzing components of the tear film (the “**Study**” and the “**Technology**”).

This announcement follows BioLight's immediate report dated May 29, 2023, regarding the signing of a cooperation agreement with a subsidiary of AstraZeneca, Alexion AstraZeneca Rare Disease (“**Alexion**”), to conduct the Study.

Approximately 40 participants are expected to participate in the Study, which is being conducted at the Tel Aviv Sourasky Medical Center (Ichilov). The tear composition analysis will be carried out by Prof. Yifat Merbl, currently at the Weizmann Institute of Science, who is one of the inventors of the technology.

BioLight estimates that, based on and subject to the rate of participant recruitment, the Study is expected to be completed in the fourth quarter of 2024.

To the best of BioLight’s knowledge, the ability to identify retinal diseases through tear sampling is groundbreaking and highly innovative, with significant commercial potential.

Forward-Looking Statement – *The information, details, and assessments BioLight included in this report regarding the cooperation, potential of the Study, rate of participant recruitment, study results, chances of success, and potential cooperation outcomes are "forward-looking information" as defined in the Securities Law, 1968. This information is subject to high uncertainty and is based, among other things, on third-party factors and many variables that BioLight does not necessarily control. Therefore, the information, details, and assessments mentioned above may not materialize, may not fully materialize, or may materialize in a materially different manner than initially estimated or anticipated.*

